BOCA RATON, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB) (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational ...

The company’s reliance on future clinical trial results introduces significant uncertainty regarding the potential success of its drug candidates, highlighting risks that may deter investors. The ...

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the ...

Shares of INmune Bio, Inc (INMB) rose over 6% in pre-market trading on Thursday, after the company said it has received ...

The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive. Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. ...

Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO ...

Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval ...

BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (INMB) (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that ...

Released top-line data from the MINDFuL phase 2 trial in 208 patients with MCI and early Alzheimer’s. The trial missed its primary cognitive endpoints in the 200 modified mITT patients enrolled, ...

Top-line results from the MINDFuL phase 2 trial in Alzheimer’s expected in the second half of June. Presented baseline demographics and disease profiles of participants in the MINDFuL phase II study ...